Scientists investigated in vitro, ex vivo and in vivo effects of a novel chemical compound targeting HCK inhibition, in combination with the most used drugs for the treatment of myelodysplastic syndrome and de novo acute myeloid leukemia, 5-Azacytidine and Cytarabine.
[Cancer Immunology Immunotherapy]
7992332
BBBBBBBB
items
1
apa
0
default
asc
1
170853
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
